User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells.

  1. Altman JD, Moss PAH, Goulder PJR, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94–96
  2. Brändle D, Bilsborough J, Rülicke T, Uyttenhove C, Boon T, Van den Eynde BJ (1998) The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection. Eur J Immunol 28:4010–4019
  3. Chaux P, Luiten R, Demotte N, Vantomme V, Stroobant V, Traversari C, Russo V, Schultz E, Cornelis GR, Boon T, van der Bruggen P (1999) Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J Immunol 163:2928–2936
  4. Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P (1999) Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med 189:767–777
  5. Chaux P, Lethé B, Van Snick J, Corthals J, Schultz ES, Cambiaso CL, Boon T, van der Bruggen P (2001) A MAGE-1 peptide recognized on HLA-DR15 by CD4+ T cells. Eur J Immunol 31:1910–1916
  6. Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S (2001) An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 61:5544–5551
  7. Corbière V, Nicolay H, Russo V, Stroobant V, Brichard V, Boon T, van der Bruggen P (2004) Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors. Tissue Antigens 63:453–457
  8. De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora J-P, De Smet C, Brasseur F, van der Bruggen P, Lethé B, Lurquin C, Brasseur R, Chomez P, De Backer O, Cavenee W, Boon T (1994) Structure, chromosomal localization and expression of twelve genes of the MAGE family. Immunogenetics 40:360–369
  9. Driscoll J, Brown M, Finley D, Monaco J (1993) MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature 365:262–264
  10. Espevik T, Nissen-Meyer J (1986) A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 95:99–105
  11. Gotter J, Brors B, Hergenhahn M, Kyewski B (2004) Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J Exp Med 199:155–166
  12. HAAS GILBERT G., D'CRUZ OSMOND J., DE BAULT LAWRENCE E., Distribution of Human Leukocyte Antigen-ABC and -D/DR Antigens in the Unfixed Human Testis, 10.1111/j.1600-0897.1988.tb00234.x
  13. Hansen MB, Nielsen SE, Berg K (1989) Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119:203–210
  14. Hernandez J., Ko A., Sherman L. A., CTLA-4 Blockade Enhances the CTL Responses to the p53 Self-Tumor Antigen, 10.4049/jimmunol.166.6.3908
  15. Kobayashi T, Lonchay C, Colau D, Demotte N, Boon T, van der Bruggen P (2003) New MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A1 tumor cells. Tissue Antigens 62:426–432
  16. Kuckelkorn U, Frentzel S, Kraft R, Kostka S, Groettrup M, Kloetzel PM (1995) Incorporation of major histocompatibility complex-encoded subunits LMP2 and LMP7 changes the quality of the 20S proteasome polypeptide processing products independent of interferon-gamma. Eur J Immunol 25:2605–2611
  17. Lehmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, Boon T, Coulie PG (1995) Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 25:340–347
  18. Lonchay C, van der Bruggen P, Connerotte T, Hanagiri T, Coulie P, Colau D, Lucas S, Van Pel A, Thielemans K, van Baren N, Boon T (2004) Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci USA 101:14631–14638
  19. Lucas S, De Smet C, Arden KC, Viars CS, Lethé B, Lurquin C, Boon T (1998) Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. Cancer Res 58:743–752
  20. Luiten R, van der Bruggen P (2000) A MAGE-A1 peptide is recognized on HLA-B7 human tumors by cytolytic T lymphocytes. Tissue Antigens 55:149–152
  21. Luiten RM, Demotte N, Tine J, van der Bruggen P (2000) A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules. Tissue Antigens 56:77–81
  22. Lurquin C, De Smet C, Brasseur F, Muscatelli F, Martelange V, De Plaen E, Brasseur R, Monaco AP, Boon T (1997) Two members of the human MAGEB gene family located in Xp.21.3 are expressed in tumors of various histological origins. Genomics 46:397–408
  23. Marsh SGE, Parham P, Barber LD (eds) (2000) The HLA FactsBook. Academic Press, London
  24. Mavilio F, Ferrari G, Rossini S, Nobili N, Bonini C, Casorati G, Traversari C, Bordignon C (1994) Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer. Blood 83:1988–1997
  25. Morel S, Lévy F, Burlet-Schiltz O, Brasseur F, Probst-Kepper M, Peitrequin A-L, Monsarrat B, Van Velthoven R, Cerottini J-C, Boon T, Gairin JE, Van den Eynde BJ (2000) Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 12:107–117
  26. Pascolo S, Schirle M, Guckel B, Dumrese T, Stumm S, Kayser S, Moris A, Wallwiener D, Rammensee HG, Stevanovic S (2001) A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry. Cancer Res 61:4072–4077
  27. Rammensee H-G, Weinschenk T, Gouttefangeas C, Stevanovic S (2002) Towards patient-specific tumor antigen selection for vaccination. Immunol Rev 188:164–176
  28. Rock KL, Goldberg AL (1999) Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 17:739–779
  29. Schirle M, Keilholz W, Weber B, Gouttefangeas C, Dumrese T, Becker HD, Stevanovic S, Rammensee H-G (2000) Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur J Immunol 30:2216–2225
  30. Schultz ES, Chapiro J, Lurquin C, Claverol S, Burlet-Schiltz O, Warnier G, Russo V, Morel S, Levy F, Boon T, Van den Eynde BJ, van der Bruggen P (2002) The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome. J Exp Med 195:391–399
  31. Sette A, Fikes J (2003) Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opin Immunol 15:461–470
  32. Stefanski H. E., Jameson S. C., Hogquist K. A., Positive Selection Is Limited by Available Peptide-Dependent MHC Conformations, 10.4049/jimmunol.164.7.3519
  33. Tanzarella S, Russo V, Lionello I, Dalerba P, Rigatti D, Bordignon C, Traversari C (1999) Identification of a promiscuous T cell epitope encoded by multiple members of the MAGE family. Cancer Res 59:2668–2674
  34. Toes REM, Nussbaum AK, Degermann S, Schirle M, Emmerich NPN, Kraft M, Laplace C, Zwinderman A, Dick TP, Müller J, Schönfisch B, Schmid C, Fehling H-J, Stevanovic S, Rammensee HG, Schild H (2001) Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J Exp Med 194:1–12
  35. Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T (1992) A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 176:1453–1457
  36. Traversari C, van der Bruggen P, Van den Eynde B, Hainaut P, Lemoine C, Ohta N, Old L, Boon T (1992) Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics 35:145–152
  37. Van den Eynde BJ, Morel S (2001) Differential processing of class-1-restricted epitopes by the standard proteasome and the immunoproteasome. Curr Opin Immunol 13:147–153
  38. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643–1647
  39. van der Bruggen P, Szikora J-P, Boël P, Wildmann C, Somville M, Sensi M, Boon T (1994) Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. Eur J Immunol 24:2134–2140
  40. van der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van den Eynde BJ, Brasseur F, Boon T (2002) Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 188:51–64
Bibliographic reference Ottaviani, Sabrina ; Zhang, Yi ; Boon, Thierry ; van der Bruggen, Pierre. A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells.. In: Cancer Immunology, Immunotherapy : other biological response modifications, Vol. 54, no. 12, p. 1214-1220 (2005)
Permanent URL http://hdl.handle.net/2078.1/12804